|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Cyclin-Dependent Kinase 6 (CDK6) antibody
|Synonyms||PLSTIRE, MGC59692, Crk2, AI504062, 5830411I20, CDK6|
Alternatives ELISA, Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
|5 references available|
|Quantity||0.1mg (0.5 mg/ml)|
|Price||450.00 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 2 to 3 Business Days|
|Immunogen||CDK6 (NP_001250, 3 a.a. ~ 100 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 K|
|Description||Other names: MGC59692, PLSTIREcyclin-dependent kinase 6|
|Characteristics||Purified Mouse Monoclonal Antibody (Mab)|
|Specificity||CDK6 (NP_001250, 3 a.a. ~ 100 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Molecular Weight||36938 DA|
Background: The protein encoded by this gene is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of Saccharomyces cerevisiae cdc28, and Schizosaccharomyces pombe cdc2, and are known to be important regulators of cell cycle progression. This kinase is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression and G1/S transition. The activity of this kinase first appears in mid-G1 phase, which is controlled by the regulatory subunits including D-type cyclins and members of INK4 family of CDK inhibitors. This kinase, as well as CDK4, has been shown to phosphorylate, and thus regulate the activity of, tumor suppressor protein Rb. Expression of this gene is up-regulated in some types of cancer. Multiple alternatively spliced variants, encoding the same protein, have been identified.
|Application Notes||ELISA ~~ 1ug/ml~3ng/ml Western blot ~~ 1:500~1000 Immunohistochemistry ~~ 1.5ug/ml Immunofluorescence|
|Buffer||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Maintain refrigerated at 2-8 deg C for up to 6 months. For long term storage store at -20 deg C in small aliquots to prevent freeze-thaw cycles|
|Research Area||Phospho-specific antibodies, Protein Modifications, Cancer, Cell Cycle, Cell Structure|
|Restrictions||For Research Use only|
van der Helm-van Mil, Toes, Huizinga: "Genetic variants in the prediction of rheumatoid arthritis." in: Annals of the rheumatic diseases, Vol. 69, Issue 9, pp. 1694-6, 2010 (PubMed).
Liu, Wu, Chen et al.: "A Large-scale genetic association study of esophageal adenocarcinoma risk." in: Carcinogenesis, Vol. 31, Issue 7, pp. 1259-63, 2010 (PubMed).
Wiedemeyer, Dunn, Quayle et al.: "Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, Issue 25, pp. 11501-6, 2010 (PubMed).
Zhao, Li, Bradfield et al.: "The role of height-associated loci identified in genome wide association studies in the determination of pediatric stature." in: BMC medical genetics, Vol. 11, pp. 96, 2010 (PubMed).
Bailey, Xie, Do et al.: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, 2010 (PubMed).